{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T16:30:44Z","timestamp":1772814644932,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1136\/ard.2008.088179","type":"journal-article","created":{"date-parts":[[2008,12,16]],"date-time":"2008-12-16T18:42:44Z","timestamp":1229452964000},"page":"153-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["Tocilizumab for multirefractory adult-onset Still\u2019s disease"],"prefix":"10.1016","volume":"68","author":[{"given":"M","family":"De Bandt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Saint-Marcoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2008.088179_bib1","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/ncprheum0510","article-title":"Adult-onset Still\u2019s disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy?","volume":"3","author":"Efthimiou","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1136\/ard.2008.088179_bib2","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.clim.2004.03.023","article-title":"Adult Still\u2019s disease reflects a Th2 rather than a Th1 cytokine profile.","volume":"112","author":"Saiki","year":"2004","journal-title":"Clin Immunol"},{"key":"10.1136\/ard.2008.088179_bib3","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/ard.2004.024026","article-title":"Club Rhumatismes et Inflammation. Tumour necrosis factor alpha blocking agents in refractory adult Still\u2019s disease: an observational study of 20 cases.","volume":"64","author":"Fautrel","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.088179_bib4","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/ard.2005.047621","article-title":"Successful treatment of refractory adult onset Still\u2019s disease with rituximab.","volume":"65","author":"Ahmadi-Simab","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.088179_bib5","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.2007.076034","article-title":"Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still\u2019s disease. Preliminary experience in France.","volume":"67","author":"Lequerr\u00e9","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.088179_bib6","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1248\/bpb.30.2001","article-title":"Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases.","volume":"30","author":"Ohsugi","year":"2007","journal-title":"Biol Pharm Bull"},{"issue":"suppl 9","key":"10.1136\/ard.2008.088179_bib7","article-title":"IL-6 receptor inhibition with tocilizumab reduces disease activity in patients with rheumatoid arthritis with inadequate response to a range of DMARDs: the TOWARD Study [abstract].","volume":"56","author":"Genovese","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"Suppl II","key":"10.1136\/ard.2008.088179_bib8","first-page":"87","article-title":"Tocilizumab, a novel monoclonal antibody targeting IL-6 signalling, significantly reduces disease activity in patients with rheumatoid arthritis [abstract].","volume":"66","author":"Smolen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.088179_bib9","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/ard.2006.068064","article-title":"Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab.","volume":"66","author":"Nishimoto","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.088179_bib10","doi-asserted-by":"crossref","first-page":"R1281","DOI":"10.1186\/ar1826","volume":"7","author":"Woo","year":"2005","journal-title":"Arthritis Res Ther"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724426770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724426770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2008.088179","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T05:11:54Z","timestamp":1736140314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724426770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S0003496724426770"],"URL":"https:\/\/doi.org\/10.1136\/ard.2008.088179","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tocilizumab for multirefractory adult-onset Still\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2008.088179","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 2009 Published by Elsevier Inc. Publishing Group and European League Against Rheumatism. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}